The study compared the levels of MMP-2,7,8,9, and TIMP-1 in blood serum of healthy people (N=97) and patients with primary renal cell carcinoma (N=93) to assess relevance of these markers to prognosis of overall survival of these patients, which were followed-up over 1 to 45 months (median 26 months). To evaluate the survival with the Kaplan—Meier estimator, the median values of examined markers in the total group of patients were taken as the threshold levels. This estimator showed that the high levels of serum MMP-7 and MMP-8 were indicative for unfavorable prognosis in the total group of patients with renal cell cancer. Of them, the most significant marker was the level of MMP-7: at its low level (<6.3 ng/ml), a 3-year survival was 93%, whereas survival dropped down to 51% at a higher value of this marker (p<0.001). For MMP-8, the threshold level was 51 ng/ml, and the corresponding survivals were 78 and 58% (p<0.01). The level of MMP-7 was also prognostically significant for the patients with stage I kidney cancer: during a 3-year follow-up, all the patients with low MMP-7 were alive, while the 3-year survival of the patients with a high level of MMP-7 was only 72% (p=0.02). There were the declining trends for survival at high TIMP-1 and low MMP-2. In contrast, the level of MMP-9 virtually did not correlate with survival of the patients with renal cell cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gershtein ES, Kushlinskii NE. Clinical Prospects of Tumor-Associated Proteases and Their Tissue Inhibitors Investigation in Oncologic Patients. Vestn. Ross. Akad. Med. Nauk. 2013;68(5):16-27. Russian.
Gershtein ES, Mushtenko VV, Korotkova EA, Bezhanova SD, Morozov AA, Alferov AA, Kazantseva IA, Kushlinskii NE. Matrix metalloproteinases 2, 7, 8, 9 and their type 1 tissue inhibitor in serum of renal cancer patients: clinical and pathologic correlations. Al’manakh Klin. Med. 2017;45(2):94-101. Russian.
Cheng HP, Duan YR, Li Y, Li XD, Zhu CY, Chen BP. Clinicopathological significance of matrix metalloproteinase-2 protein expression in renal cell carcinoma patients. Anal. Quant. Cytopathol. Histpathol. 2016;37(6):353-363.
Deryugina EI, Quigley JP. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim. Biophys. Acta. 2010;1803(1):103-120.
Gershtein ES, Korotkova EA, Prorokov VV, Kushlinsky NE. Matrix metalloproteinases 2, 3, 13 and their type 2 tissue inhibitor in tumors and plasma of patients with colorectal cancer. Bull. Exp. Biol. Med. 2008;145(3):362-366.
Gershtein ES, Korotkova EA, Shcherbakov AM, Prorokov VV, Golovkov DA, Kushlinskii NE. Matrix metalloproteinases 7 and 9 and their types 1 and 4 tissue inhibitors in tumors and plasma of patients with colorectal cancer. Bull. Exp. Biol. Med. 2007;143(4):459-462.
Gershtein ES, Levkina NV, Digayeva MA, Laktionov KP, Tereshkina IV, Kushlinsky NE. Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms. Bull. Exp. Biol. Med. 2010;149(5):628-631.
Gershtein ES, Mushtenko SV, Ermilova VD, Levchenko NE, Kushlinskii NE. Matrix metalloproteinases and their tissue inhibitors in blood serum of patients with endometrial cancer: clinical and morphological correlations. Bull. Exp. Biol. Med. 2018;165(1):75-79.
Kushlinskii NE, Gershtein ES, Ivannikov AA, Davydov MM, Chang VL, Ognerubov NA, Stilidi IS. Clinical significance of matrix metalloproteinases in blood plasma of patients with gastric cancer. Bull. Exp. Biol. Med. 2019;166(3):373-376.
Kuusk T, Albiges L, Escudier B, Grivas N, Haanen J, Powles T, Bex A. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Angiogenesis. 2017;20(2):205-215.
Niedworok C, vom Dorp F, Tschirdewahn S, Rübben H, Reis H, Szucs M, Szarvas T. Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method. Int. Urol. Nephrol. 2016;48(3):355-361.
Qiao ZK, Li YL, Lu HT, Wang KL, Xu WH. Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma. World J. Surg. Oncol. 2013;11. https://doi.org/10.1186/1477-7819-11-1
Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Jung K. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas. Cancer Sci. 2008;99(6):1188-1194.
Soleyman-Jahi S, Nedjat S, Abdirad A, Hoorshad N, Heidari R, Zendehdel K. Prognostic significance of matrix metalloproteinase-7 in gastric cancer survival: a meta-analysis. PLoS One. 2014;10(4). ID e0122316. doi: 10.1371/journal.pone.0122316
Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH, Lin JT. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin. Cancer Res. 2007;13(7):2054-2060.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 168, No. 11, pp. 619-623, November, 2019
Rights and permissions
About this article
Cite this article
Kushlinskii, N.E., Gershtein, E.S., Alferov, A.A. et al. Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer. Bull Exp Biol Med 168, 673–676 (2020). https://doi.org/10.1007/s10517-020-04778-w
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-020-04778-w